We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Expert Opinion / Cases · October 19, 2015

Metastatic Disease on Votrient

Written by
Andrew Fintel DO


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • George Yaghmour

    Interesting to share. Votrient is better tolerable with better quality of life than sunitinib according to NEJM 2014 papers. However, reviewing the patient medication especially if he is taking any drug would interact and suppress the liver metabolism by Cytochrome should be considered and 400 mg should be considered. While the patient having HTN and other side effects revealing better efficacy,and side effect management and symptoms control would help. if the symptoms is affecting the daily life activity and grade 3-4 would consider switching to other TKI. In this case restating images to evaluate efficacy in 6-8 weeks interval per the trial protocol. So I would suggest to repeat scan and discuss either to continue with symptoms support and reduce to 400 then increase back slowly or switch to Sutent or other TKI.

  • Angel Rodriguez

    If there is objective response to pazopanib, lower doses to control toxicity. I've seen response to pazopanib at dose of 200 mg/day.

  • Alberto Palma

    I believe that under pazopanib doses can reduce the toxicity of this patient, but I fear that this doosagens are not really effective in the treatment of renal tumors. Trade to Temsorolimus because it was the only drug that showed overall survival gain in such a scenario disease, when the disease can be classified as high risk, or even Interferon and bevacizumab, is also there to Temsirolimus prohibitive toxicity.

  • George Yaghmour

    Would also might consider of PD1/PDL1, molecular alteration testing if possible and checkpoint inhibitors therapy.

  • Oct 31, 2020

    Pending Moderator approval.

Further Reading